Ketoconazole in atopic dermatitis: therapeutic response is correlated with decrease in serum IgE.
The prevalence of specific IgE antibodies to the yeasts Pityrosporum orbiculare and Candida albicans was investigated in adult patients with atopic dermatitis (AD) or with seborrhoeic dermatitis and in healthy controls by means of the radioallergosorbent test (RAST). Of 63 AD patients, 28 (44%) had IgE antibodies to P. orbiculare and 21 (33%) to C. albicans. This is highly significant, since no antibodies were found in sera from other patients or controls. With the intention to treat, 20 patients with AD and a positive RAST to P. orbiculare were given ketoconazole 200 mg daily for 2 months and 200 mg twice weekly for further 3 months. The clinical scores improved during treatment with a reduction in the levels of specific IgE to P. orbiculare and total serum IgE. However, there were no correlations between clinical score and serum levels of P. orbiculare-specific IgE. C. albicans-specific IgE, on the other hand, correlated both with clinical score and with total serum IgE.
Bäck
O
O
Department of Dermatology, University Hospital, Umeå, Sweden.
Scheynius
A
A
Johansson
S G
SG
D000293:Adolescent; D000328:Adult; D000908:Antibodies, Fungal / Q000097:blood*; D002176:Candida albicans / Q000276:immunology*; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood*; D007654:Ketoconazole / Q000627:therapeutic use*; D008290:Malassezia / Q000276:immunology*; D008297:Male; D008875:Middle Aged
D000908:Antibodies, Fungal; D007073:Immunoglobulin E; D007654:Ketoconazole